Department of Hematology, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos (HCSC), Madrid, Spain.
Department of Emergency, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos (HCSC), Madrid, Spain.
Transfus Apher Sci. 2022 Apr;61(2):103413. doi: 10.1016/j.transci.2022.103413. Epub 2022 Mar 11.
Platelets are the blood cells in charge of maintaining the body hemostasis, recognising the damaged vessel wall, and providing the appropriate cellular surface for the coagulation cascade to act locally. Additionally, platelets are active immunomodulators. At the crossroads of hemostasis and inflammation, platelets may exert either beneficial actions or participate in pathological manifestations, and have been associated with the prothrombotic nature of multi-organ failure in systemic inflammation. Platelet number alterations have been reported in septis, and platelet transfusions are given to thrombocytopenic patients. However, the risk to develop transfusion related acute lung injury (TRALI) is higher in sepsis patients. In this manuscript we show that platelets produced during inflammation in preclinical mouse models of sterile inflammation display lower aggregation capacity when stimulating certain receptors, while responses through other receptors remain intact, and we name them "inflammation-conditioned" platelets. In a cohort of sepsis patients, we observed, as previously reported, alterations in the number of platelets and platelet hyperreactivity. Furthermore, we identified a receptor-wise platelet aggregation response disbalance in these patients, although not similar to platelets from preclinical models of sterile inflammation. Interestingly, we generated evidence supporting the notion that platelet aggregation capacity disbalance was partially triggered by plasma components from sepsis patients. Our findings have implications in the indication of platelet transfusions in sepsis patients: Are fully functional platelets suitable for transfusion in sepsis patients? Current Clinical Trials (RESCUE) will answer whether platelet production stimulation with thrombopoietin receptor agonists (TPO-RAs) could be a substitute of platelet transfusions.
血小板是负责维持身体止血、识别受损血管壁并为凝血级联反应提供适当细胞表面以局部作用的血细胞。此外,血小板是活跃的免疫调节剂。在止血和炎症的交汇处,血小板可能发挥有益作用或参与病理表现,并与全身炎症多器官衰竭的促血栓形成性质有关。在败血症中已经报道了血小板数量的改变,并且给血小板减少症患者输注血小板。然而,在败血症患者中,发生输血相关急性肺损伤(TRALI)的风险更高。在本手稿中,我们表明,在无菌炎症的临床前小鼠模型中炎症期间产生的血小板在刺激某些受体时显示出较低的聚集能力,而通过其他受体的反应仍然完整,我们将它们命名为“炎症条件”血小板。在一组败血症患者中,我们观察到了以前报道的血小板数量和血小板高反应性的改变。此外,我们在这些患者中确定了一种受体特异性的血小板聚集反应失衡,但与无菌炎症的临床前模型中的血小板不同。有趣的是,我们提供了证据支持这样的观点,即血小板聚集能力失衡部分是由败血症患者的血浆成分触发的。我们的发现对败血症患者血小板输注的适应症有影响:功能齐全的血小板是否适合败血症患者输注?目前的临床试验(RESCUE)将回答血小板生成刺激素受体激动剂(TPO-RA)是否可以替代血小板输注。